| Primary | Number of Participants With Gastric Ulcer and/or Duodenal Ulcer | The number of participants that developed gastric ulcer and/or duodenal ulcer at month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater. | Participants not taking investigational drug were not included. | Posted | | Number | | participants | | 18 Months | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Log Rank | | <0.0001 | | Hazard Ratio (HR) | 0.0989 | | | 2-Sided | 95 | 0.0425 | 0.2300 | | | | No | Superiority or Other | | |
|
| Secondary | Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect < 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect < 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury. | Values are from the Full Analysis Set. | Posted | | Median | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect < 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect < 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect < 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions). Erosions are defined as mucosal defect < 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions). Erosions are defined as mucosal defect < 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions). Erosions are defined as mucosal defect < 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions). Erosions are defined as mucosal defect < 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18) | The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions). Erosions are defined as mucosal defect < 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage) | Number of participants with gastric or duodenal ulcer or gastric or duodenal hemorrhagic lesion (upper gastrointestinal hemorrhage) from baseline through month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater. | Values are from the Full Analysis Set. | Posted | | Number | | participants | | 18 Months | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3) | Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6) | Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 9) | Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12) | Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18) | Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3) | Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6) | Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 9) | Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12) | Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18) | Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3) | Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6) | Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 9) | Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12) | Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18) | Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3) | Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6) | Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 9) | Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12) | Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18) | Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3) | Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6) | Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 9) | Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12) | Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18) | Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3) | Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6) | Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 9) | Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12) | Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18) | Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3) | Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 3. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6) | Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 6. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 9) | Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 9. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12) | Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 12. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18) | Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom. | No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set. | Posted | | Mean | Standard Deviation | scores on a scale | | Baseline and Month 18. | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |
| Secondary | Number of Participants With Adverse Events | Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug. A TEAE may also be a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Please see Other Adverse Events table below for TEAE listings. | | Posted | | Number | | participants | | 18 Months | | | | ID | Title | Description |
|---|
| OG000 | Lansoprazole 15 mg QD | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months. | | OG001 | Gefarnate 50 mg BID | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months. |
| |